



Liste modèle des médicaments essentiels



Acenocoumarol [Informations générales](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [warfarin](#) pour [Other specified diseases of arteries or arterioles](#) Therapeutic equivalent to [warfarin](#) pour [Venous thromboembolism](#) Therapeutic equivalent to [warfarin](#) pour [Cerebral ischaemic stroke due to embolic occlusion](#) Therapeutic equivalent to [warfarin](#) pour [Atrial fibrillation](#)



Apixaban [Informations générales](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) pour [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) pour [Venous thromboembolism](#)



Cyanocobalamin [Informations générales](#)

Section

Antianaemia medicines

◦ .

Indications

[Anaemias or other erythrocyte disorders](#)



Dabigatran [Informations générales](#)

Section

Medicines affecting coagulation

◦ Oral > Solid: 110 mg; 150 mg

Indications

[Other specified atrial fibrillation](#) [Venous thromboembolism](#)



Dalteparin [Informations générales](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) pour [Venous thromboembolism](#) Therapeutic equivalent to [enoxaparin](#) pour [Acute ischaemic heart disease](#)



Darbepoetin alfa [Informations générales](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) pour [Anaemia due to chronic disease](#)

Deferasirox [Informations générales](#)

Section

Medicines for haemoglobinopathies

◦ Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg

◦ Oral > Solid > tablet: 90 mg; 180 mg; 360 mg

Indications

[Other specified sickle cell disorders or other haemoglobinopathies](#) [Thalassaemias](#)

Deferiprone [Informations générales](#)

Section

Medicines for haemoglobinopathies

Indications

Therapeutic equivalent to [deferiasirox](#) pour [Other specified sickle cell disorders or other haemoglobinopathies](#)

Therapeutic equivalent to [deferiasirox](#) pour [Thalassaemias](#)

Deferoxamine [Informations générales](#)

Section

Medicines for haemoglobinopathies

◦ Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)

Indications

[Other specified sickle cell disorders or other haemoglobinopathies](#) [Thalassaemias](#)

Desmopressin [Informations générales](#)

Section

Medicines affecting coagulation

◦ Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)

◦ Local > Nasal > Spray: 150 µg per actuation (acetate)

Indications

[Haemophilia A Von Willebrand disease](#)

Edoxaban [Informations générales](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) pour [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#)

pour [Venous thromboembolism](#)

Emicizumab [Informations générales](#)

Section

Medicines affecting coagulation

◦ Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial

Indications

[Haemophilia A](#)

Enoxaparin [Informations générales](#)

Section

Medicines affecting coagulation

◦ Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule;

80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule

Indications

[Venous thromboembolism Acute ischaemic heart disease](#)

Epoetin alfa [Informations générales](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) pour [Anaemia due to chronic disease](#)

Epoetin beta [Informations générales](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) pour [Anaemia due to chronic disease](#)

Epoetin theta [Informations générales](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) pour [Anaemia due to chronic disease](#)

Erythropoiesis-stimulating agents [Informations générales](#)

Section

Antianaemia medicines

- Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe

Indications

[Anaemia due to chronic disease](#)

Ferrous salt [Informations générales](#)

Section

Antianaemia medicines

- Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
- Oral > Solid > tablet: 60 to 65 mg elemental iron

Indications

[Iron deficiency anaemia](#)

Ferrous salt + folic acid [Informations générales](#)

Section

Antianaemia medicines

- Oral > Solid: 60 mg iron + 2.8 mg
- Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg

Indications

[Iron deficiency anaemia Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida](#)

Folic acid [Informations générales](#)

Section

Antianaemia medicines

- Oral > Solid: 400 µg
- Oral > Liquid: 1 mg per mL
- Oral > Solid: 1 mg tablet; 5 mg tablet

Indications

[Cephalocele Anencephaly or similar anomalies Spina bifida Folate deficiency anaemia](#)

Heparin sodium [Informations générales](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial

Indications

[Acute ischaemic heart disease](#) [Unstable angina](#) [Venous thromboembolism](#)

Hydroxocobalamin [Informations générales](#)

Section

Antianaemia medicines

- Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)

Indications

[Megaloblastic anaemia due to vitamin B12 deficiency](#)

Hydroxycarbamide (hydroxyurea) [Informations générales](#)

Section

Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

[Other specified sickle cell disorders or other haemoglobinopathies](#)

Methoxy polyethylene glycol-epoetin beta [Informations générales](#)

Section

Antianaemia medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) pour [Anaemia due to chronic disease](#)

Nadroparin [Informations générales](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [enoxaparin](#) pour [Venous thromboembolism](#) Therapeutic equivalent to [enoxaparin](#) pour [Acute ischaemic heart disease](#)

Phytomenadione [Informations générales](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution; 1 mg per 0.5 mL in ampoule
- Oral > Solid > tablet: 5 mg tablet

Indications

[Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors](#) [Haemorrhagic or haematological disorders of fetus or newborn](#)

Protamine sulfate [Informations générales](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial

Indications

[Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors](#)

Rivaroxaban [Informations générales](#)

Section

Medicines affecting coagulation

Indications

Therapeutic equivalent to [dabigatran](#) pour [Other specified atrial fibrillation](#) Therapeutic equivalent to [dabigatran](#) pour [Venous thromboembolism](#)



Tranexamic acid [Informations générales](#)

Section

Medicines affecting coagulation

- Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

[Haemorrhage, not elsewhere classified](#)



Warfarin [Informations générales](#)

Section

Medicines affecting coagulation

- Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
- Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)

Indications

[Other specified diseases of arteries or arterioles](#) [Venous thromboembolism](#) [Cerebral ischaemic stroke due to embolic occlusion](#) [Atrial fibrillation](#)